Provided by Tiger Trade Technology Pte. Ltd.

Pacific Biosciences of California

2.51
+0.14005.91%
Post-market: 2.49-0.0190-0.76%18:27 EDT
Volume:35.85M
Turnover:87.72M
Market Cap:779.32M
PE:-5.82
High:2.56
Open:2.34
Low:2.32
Close:2.37
52wk High:2.73
52wk Low:1.07
Shares:310.49M
Float Shares:302.00M
Volume Ratio:1.27
T/O Rate:11.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4310
EPS(LYR):-1.8215
ROE:-929.32%
ROA:-14.07%
PB:-23.46
PE(LYR):-1.38

Loading ...

NASD Most Active Issues

Dow Jones
·
Yesterday

Pacific Biosciences up over 30%, on Pace for Largest Percent Increase Since July 2024

Dow Jones
·
Yesterday

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
Sep 11

PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference

GlobeNewswire
·
Sep 04

PacBio Releases Transcript of 2Q26 Earnings Call

Reuters
·
Aug 07

10x Genomics Q2 Revenue Rises on Atera Demand

Reuters
·
Aug 07

Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)

TIPRANKS
·
Aug 06

PacBio CEO Christian Henry steps down, Mark Van Oene succeeds

TIPRANKS
·
Aug 06

Pacific Biosciences of California, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Pacific Biosciences of California Appoints New CEO, Plans to Cut 8% of Workforce

Dow Jones
·
Aug 06

Pacific Biosciences of California - Expects $30 Mln-$40 Mln Annualized Operating Expense Reduction by End of 2027 - SEC Filing

THOMSON REUTERS
·
Aug 06

Pacific Biosciences of California - Restructuring to Reduce Workforce by About 8% - SEC Filing

THOMSON REUTERS
·
Aug 06

PacBio Q2 2026 Earnings: Consumables Growth Could Not Prevent Margin Compression

TradingKey
·
Aug 06

Pacific Biosciences Q2 Adj. Loss Bigger than Estimates on Margin Pressure

Reuters
·
Aug 06

Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate

Benzinga Earnings
·
Aug 06

Pacific Biosciences of California - Christian Henry Steps Down as President and CEO

THOMSON REUTERS
·
Aug 06

Pacbio Appoints Mark Van Oene as President and Chief Executive Officer

THOMSON REUTERS
·
Aug 06

Pacific Biosciences of California, - Appoints Mark Van Oene as President and CEO Effective August 5, 2026

THOMSON REUTERS
·
Aug 06

Press Release: PacBio Appoints Mark Van Oene as President and Chief Executive Officer

Dow Jones
·
Aug 06

Pacific Biosciences of California: Pacbio Expects Revenue for the Fy2026 to be in the Range of $155 Million to $165 Million

THOMSON REUTERS
·
Aug 06